Kardigan, Inc.

NASDAQ:KARD

Biotechnology

Healthcare
$12.32 +3.50%

+$0.77 today

Market cap
$1.10B
Beta
0.00
52W Low $16.25High $24.00

Volume 0.55M

Average 5.84M

KARD Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

No reported Gross Profit figures are available to summarize.

Gross Profit history

Currency unavailable · from the income statement

No Gross Profit data reported for this period type.

Gross Profit vs competitors

How KARD compares with its peers on the latest reported figures

KARD Competitors
Gross Profit for KARD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CYTKCytokinetics, IncorporatedLTM Jun 2026$62.98M USD-26.5%—88.7%
RNAAtrium Therapeutics, Inc.FY2025$18.62M USD——100.0%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$6.56M USD-89.7%-39.8%92.1%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$326K USD+115.4%—144.9%
IKTInhibikase Therapeutics, Inc.LTM Mar 2026$0 USD+100.0%——
KARDKardigan, Inc.—— ———
Peer median (excluding KARD) —+36.7%-39.8%96.1%

Competitors are the stored peer set for KARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kardigan, Inc.

NASDAQ:KARD

Intrinsic Alpha fair value

Locked

Current Price

$12.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.